Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of formula I, or a pharmaceutically acceptable salt thereof:

wherein

 R^1 is selected from C_{3-6} alkyl, C_{6-10} aryl, C_{2-9} heteroaryl, C_{6-10} aryl- C_{1-4} alkyl, C_{2-9} heteroaryl- C_{1-4} alkyl, C_{3-10} cycloalkyl, C_{3-10} cycloalkyl- C_{1-4} alkyl, R^8 -C(=O)-, R^8 - $S(=O)_2$ -, R^8 -S(=O)-, R^8 -S(=O)-, R^8 -S(=O)-, R^8 -S(=O)-, wherein R^8 is selected from C_{3-6} alkyl, C_{6-10} aryl, C_{2-9} heteroaryl, C_{6-10} aryl- C_{1-4} alkyl, C_{3-10} cycloalkyl, and C_{3-10} cycloalkyl- C_{1-4} alkyl, wherein said C_{3-6} alkyl, C_{6-10} aryl, C_{2-9} heteroaryl, C_{6-10} aryl- C_{1-4} alkyl, C_{2-9} heteroaryl- C_{1-4} alkyl, C_{2-9} heteroaryl- C_{1-4} alkyl, C_{2-9} heteroaryl- C_{1-4} alkyl, C_{3-10} cycloalkyl- C_{3-6} cycloalkyl-

R² is selected from -H and C₁₋₆alkyl optionally substituted with one or more groups selected from halogen, -CF₃, -OH, C₁₋₃alkoxy, and halogen; and

 R^3 is selected from -H, C_{1-6} alkyl-O-C(=O)-, C_{1-6} alkyl, C_{3-6} cycloalkyl, and C_{3-6} cycloalkyl- C_{1-4} alkyl, wherein said C_{1-6} alkyl-O-C(=O)-, C_{1-6} alkyl, C_{3-6} cycloalkyl, and C_{3-6} cycloalkyl- C_{1-4} alkyl are optionally substituted with one or more groups selected from C_{1-6} alkyl, halogenated C_{1-6} alkyl, - NO_2 , -CF₃, C_{1-6} alkoxy and halogen.

2. (Currently Amended) A compound according to claim 1, wherein

Application No. 10/533,764

Amendment Dated: February 5, 2007

Reply to Office Action mailed October 2, 2006 and Advisory Action mailed January 10, 2007

 R^1 is selected from C_{3-6} alkyl, C_{6-10} aryl, C_{2-6} heteroaryl, C_{6-10} aryl- C_{1-4} alkyl, C_{2-6} heteroaryl- C_{1-4} alkyl, C_{3-10} cycloalkyl- C_{1-4} alkyl, wherein said C_{3-6} alkyl, C_{6-10} aryl, C_{2-6} heteroaryl, C_{6-10} aryl- C_{1-4} alkyl, C_{2-6} heteroaryl- C_{1-4} alkyl, C_{3-10} cycloalkyl, C_{3-10} cycloalkyl- C_{1-4} alkyl are optionally substituted with one or more groups selected from C_{1-4} alkyl, C_{1-4} alkyl, C_{1-3} alkoxy, phenoxy, and halogen;

R² is selected from –H and C₁₋₃alkyl; and

R³ is selected from –H and C₁₋₆alkyl-O-C(=O)-.

3. (Currently Amended) A compound according to claim 2,

wherein R^{1} is R^{9} -CH₂-, wherein R^{9} is selected from phenyl, pyridyl, thienyl, furyl, imidazolyl, triazolyl, pyrrolyl, thiazolyl, N-oxido-pyridyl, benzyl, pyridylmethyl, thienylmethyl, furylmethyl, imidazolylmethyl, triazolylmethyl, pyrrolylmethyl, thiazolylmethyl and N-oxido-pyridylmethyl, optionally substituted with one or more groups selected from C_{1-4} alkyl, halogen, -CF₃, -OH, C_{1-3} alkoxy, phenoxy and halogen; and

R² and R³ are hydrogen.

4. (Currently Amended) A compound according to claim 3,

wherein R^9 is selected from benzyl, phenyl, pyridyl, thienyl, furyl, imidazolyl, pyrrolyl and thiazolyl, optionally substituted with one or more groups selected from C_{1-4} alkyl, halogen, $-CF_3$, -OH, C_{1-3} alkoxy, phenoxy, and halogen.

5. (Currently Amended) A compound according to claim 4, wherein

wherein-R⁹ is selected from benzyl, phenyl, pyridyl, thienyl, furyl, imidazolyl, pyrrolyl and thiazolyl.

6. (Currently Amended) A compound according to claim 1, wherein

 R^1 is selected from C_{3-6} alkyl, C_{3-10} cycloalkyl, and C_{3-10} cycloalkyl- C_{1-4} alkyl, wherein said C_{3-6} alkyl, C_{3-10} cycloalkyl, and C_{3-10} cycloalkyl- C_{1-4} alkyl are optionally substituted with one or more groups selected from C_{1-4} alkyl, halogen, -CF₃, -OH, C_{1-3} alkoxy, phenoxy, and halogen;

R² is –H or C₁₋₃alkyl; and

 R^3 is –H, C_{1-6} alkyl, C_{3-6} cycloalkyl, and C_{3-6} cycloalkyl- C_{1-4} alkyl, wherein said C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkyl- C_{1-4} alkyl are optionally substituted with one or more groups selected from C_{1-4} alkyl, halogen, -CF₃, -OH, C_{1-3} alkoxy, phenoxy, and halogen.

7. (Previously Presented) A compound of formula I, or a pharmaceutically acceptable salt thereof:

wherein

R¹ is selected from 1-propyl, 2-propyl, 1-butyl, 2-butyl, t-butyl, 2-methyl-1-propyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and cyclononyl;

R² is selected from –H, methyl, ethyl, 1-propyl and 2-propyl; and

R³ is selected from –H, methyl, ethyl, allyl, 3,3-dimethyl-allyl, cyclopropylmethyl, 2-methoxy-ethyl, and 3-methoxy-1-propyl.

8. (Currently Amended) A compound according to claim 1, wherein

R¹ is selected from R⁸-C(=O)-, R⁸-S(=O)₂-, R⁸-S(=O)-, R⁸-NHC(=O)-, R⁸-C(=S)- and R⁸-NH-C(=S)-, wherein R⁸ is selected from C_{3-6} alkyl, C_{6-10} aryl, C_{2-6} heteroaryl, C_{6-10} aryl- C_{1-4} alkyl, C_{2-6} heteroaryl- C_{1-4} alkyl, C_{3-10} cycloalkyl, and C_{3-10} cycloalkyl- C_{1-4} alkyl; wherein said C_{3-6} alkyl, C_{6-10} aryl, C_{2-6} heteroaryl, C_{6-10} aryl- C_{1-4} alkyl, C_{2-6} heteroaryl- C_{1-4} alkyl, C_{3-10} cycloalkyl C_{3-10} cycloalkyl C_{3-10} cycloalkyl, and C_{3-10} cycloalkyl- C_{1-4} alkyl C_{3-6} cycloalkyl- C_{1-4} alkyl are optionally substituted with C_{1-4} alkyl, C_{1-3} alkoxy, phenoxy, and halogen;

R² is -H; and

R³ is selected from –H and C₁₋₆alkyl-O-C(=O)-.

9. (original) A compound according to claim 8, wherein

R⁸ is selected from phenyl, benzyl, phenethyl and cyclohexyl, wherein said phenyl, benzyl, phenethyl and cyclohexyl are optionally substituted with one or more groups selected from methyl, methoxy and halogen.

10. (Previously Presented) A compound according to claim 1, wherein the compound is selected from:

N,N-diethyl-4-((S)piperazin-1-yl{3-[(1,3-thiazol-2-ylmethyl)amino]phenyl}methyl)benzamide;

N,N-diethyl-4-((R)-piperazin-1-yl{3-[(1,3-thiazol-2-ylmethyl)amino]phenyl}methyl)benzamide;

4-[(S)-[3-(benzylamino)phenyl](piperazin-1-yl)methyl]-N,N-diethylbenzamide;

N,N-diethyl-4-((R)-piperazin-1-yl{3-[(thien-2-ylmethyl)amino]phenyl}methyl)benzamide;

N,N-diethyl-4-((S)-piperazin-1-yl{3-[(thien-2-ylmethyl)amino]phenyl}methyl)benzamide;

N,N-diethyl-4-[(S)-{3-[(2-furylmethyl)amino]phenyl}(piperazin-1-yl)methyl]benzamide;

4-[(R)-[3-(benzylamino)phenyl](piperazin-1-yl)methyl]-N,N-diethylbenzamide;

N,N-diethyl-4-[(R)-{3-[(2-furylmethyl)amino]phenyl}(piperazin-1-yl)methyl]benzamide;

N,N-diethyl-4-((R)-piperazin-1-yl{3-[(thien-3-ylmethyl)amino]phenyl}methyl)benzamide;

N,N-diethyl-4-((S)-piperazin-1-yl{3-[(thien-3-ylmethyl)amino]phenyl}methyl)benzamide;

N,N-diethyl-4-[(R)-{3-[(3-furylmethyl)amino]phenyl}(piperazin-1-yl)methyl]benzamide;

N,N-diethyl-4-[(R)-{3-[(2-phenylethyl)amino]phenyl}(piperazin-1-yl)methyl]benzamide;

 $4-[(R)-\{3-[(cyclohexylmethyl)amino]phenyl\}(piperazin-1-yl)methyl]-N,N-diethylbenzamide;$

N,N-diethyl-4-[(R)-piperazin-1-yl(3-{[4-trifluoromethyl)benzyl]amino}phenyl)methyl]benzamide;

4-[(R)-{3-[(cyclopentylmethyl)amino]phenyl}(piperazin-1-yl)methyl]-N,N-diethylbenzamide;

4-[(S)-{3-[(cyclohexylmethyl)amino]phenyl}(piperazin-1-yl)methyl]-N,N-diethylbenzamide;

4-[(R)-{3-[(cyclohex-1-en-1-ylmethyl)amino]phenyl}(piperazin-1-yl)methyl]-N,N-diethylbenzamide;

N,N-diethyl-4-[(S)-{3-[methyl(phenyl)amino]phenyl}(piperazin-1-yl)methyl]benzamide;

N,N-diethyl-4-[(S)-{3-[ethyl(phenyl)amino]phenyl}(piperazin-1-yl)methyl]benzamide;

N,N-diethyl-4-[(R)-{3-[methyl(phenyl)amino]phenyl}(piperazin-1-yl)methyl]benzamide;

N,N-diethyl-4-[(R)-{3-[ethyl(phenyl)amino]phenyl}(piperazin-1-yl)methyl]benzamide;

4-[(R)-{3-[(cyclohexylmethyl)amino]phenyl}(piperazin-1-yl)methyl]-N,N-diethylbenzamide;

4-[(R)-[3-(cyclopentylamino)phenyl](piperazin-1-yl)methyl]-N,N-diethylbenzamide;

4-[(R)-[3-(cycloheptylamino)phenyl](piperazin-1-yl)methyl]-N,N-diethylbenzamide;

4-[(R)-[3-(cyclooctylamino)phenyl](piperazin-1-yl)methyl]-N,N-diethylbenzamide;

4-[(R)-[3-(cyclononylamino)phenyl](piperazin-1-yl)methyl]-N,N-diethylbenzamide;

4-[(S)-[3-(cyclohexylamino)phenyl](piperazin-1-yl)methyl]-N,N-diethylbenzamide;

N,N-diethyl-4-[(R)-{3-[(4-methylphenyl)amino]phenyl}(piperazin-1-yl) methyl]benzamide;

 $N, N-diethyl-4-[(S)-\{3-[(4-methylphenyl)amino]phenyl\}\ (piperazin-1-yl)methyl]benzamide;$

4-[(R)-{3-[(3-chlorophenyl)amino]phenyl}(piperazin-1-yl)methyl]-N,N-diethylbenzamide;

Reply to Office Action mailed October 2, 2006 and Advisory Action mailed January 10, 2007

```
4-[(S)-{3-[(3-chlorophenyl)amino]phenyl}(piperazin-1-yl)methyl]-N,N-diethylbenzamide;
```

4-[(R)-{3-[(2-fluorophenyl)amino]phenyl}(piperazin-1-yl)methyl]-N,N-diethylbenzamide;

4-[(S)-{3-[(2-fluorophenyl)amino]phenyl}(piperazin-1-yl)methyl]-N,N-diethylbenzamide;

4-[(R)-[3-(benzoylamino)phenyl](piperazin-1-yl)methyl]-N,N-diethylbenzamide;

N,N-diethyl-4-[(R)-{3-[(phenylacetyl)amino]phenyl}(piperazin-1-yl)methyl]benzamide;

4-[(S)-[3-(benzoylamino)phenyl](piperazin-1-yl)methyl]-N,N-diethylbenzamide;

N,N-diethyl-4-[(S)-{3-[(phenylacetyl)amino]phenyl}(piperazin-1-yl)methyl]benzamide;

N,N-diethyl-4-[(R)-{3-[(2-methyl-2-phenylpropanoyl)amino]phenyl}(piperazin-1-yl)methyl]benzamide;

N,N-diethyl-4-[(R)-(3-{[(3-fluorophenyl)acetyl]amino}phenyl)(piperazin-1-yl)methyl]benzamide;

4-[(R)-{3-[(cyclohexylacetyl)amino]phenyl}(piperazin-1-yl)methyl]-N,N-diethylbenzamide;

N,N-diethyl-4-[(R)-{3-[(3-phenylpropanoyl)amino]phenyl}(piperazin-1-yl)methyl]benzamide;

4-[(R)-{3-[(cyclohexylcarbonyl)amino]phenyl}(piperazin-1-yl)methyl]-N,N-diethylbenzamide;

N,N-diethyl-4-[(R)-{3-[(phenylsulfonyl)amino]phenyl}(piperazin-1-yl)methyl]benzamide;

4-[(R)-{3-[(benzy|sulfonyl)amino]phenyl}(piperazin-1-yl)methyl]-N,N-diethylbenzamide;

N,N-diethyl-4-[(S)-{3-[(phenylsulfonyl)amino]phenyl}(piperazin-1-yl)methyl]benzamide;

4-[(R)-{3-[(anilinocarbonyl)amino]phenyl}(piperazin-1-yl)methyl]-N,N-diethylbenzamide;

4-[(R)-{3-[(anilinocarbonothioyl)amino]phenyl}(piperazin-1-yl)methyl]-N,N-diethylbenzamide;

N, N-diethyl-4-[(S)-1-piperazinyl[3-(propylamino)phenyl]methyl]benzamide;

4-[(S)-[3-(dipropylamino)phenyl]-1-piperazinylmethyl]-*N*,*N*-diethylbenzamide;

N,N-diethyl-4-[(R)-1-piperazinyl[3-(propylamino)phenyl]methyl]benz-amide;

4-[(R)-[3-(dipropylamino)phenyl]-1-piperazinylmethyl]-N,N-diethylbenzamide;

N,*N*-diethyl-4-[(*S*)-1-piperazinyl[3-[[[4-(3-pyridinyl)phenyl]methyl]-amino]phenyl]methyl]benzamide;

N,N-diethyl-4-[(S)-[3-[[[4-(1H-imidazol-1-yl)phenyl]methyl]amino]-phenyl]-1-piperazinylmethyl]benzamide;

N,N-diethyl-4-[(S)-1-piperazinyl[3-[(2-quinolinylmethyl)amino]phenyl]-methyl]benzamide;

4-[(R)-[3-[(2,2-diphenylethyl)amino]phenyl]-1-piperazinylmethyl]-N,N-diethylbenzamide;

4-[(*R*)-[3-[[[4-(1,1-dimethylethyl)phenyl]methyl]amino]phenyl]-1-piperazinylmethyl]-*N*,*N*-diethylbenzamide;

N,N-diethyl-4-[(R)-[3-[[(4-phenoxyphenyl)methyl]amino]phenyl]-1-piperazinylmethyl]benzamide;

N,N-diethyl-4-[(R)-[4-(2-propenyl)-1-piperazinyl][3-(propylamino)-phenyl]methyl]benzamide;

N,N-diethyl-4-[(R)-[4-(2-methoxyethyl)-1-piperazinyl][3-(propylamino)-phenyl]methyl]benzamide;

Application No. 10/533,764

Amendment Dated: February 5, 2007

Reply to Office Action mailed October 2, 2006 and Advisory Action mailed January 10, 2007

N,N-diethyl-4-[(R)-[4-(3-methoxypropyl)-1-piperazinyl][3-(propylamino)phenyl]methyl]benzamide;

4-[(S)-[3-(cycloheptylamino)phenyl](piperazin-1-yl)methyl]-N,N-diethylbenzamide;

4-[(S)-[3-(cyclooctylamino)phenyl](piperazin-1-yl)methyl]-N,N-diethylbenzamide;

N,N-diethyl-4-[(S)-{3-[(3-phenylpropanoyl)amino]phenyl}(piperazin-1-yl)methyl]benzamide;

4-[(R)-(3-aminophenyl)[4-(2-propenyl)-1-piperazinyl]methyl]-N,N-diethyl- benzamide;

4-[(R)-(3-aminophenyl)[4-(3-methyl-2-butenyl)-1-piperazinyl]methyl]-N,N-diethyl-benzamide;

 $4\hbox{-}[(R)\hbox{-}(3\hbox{-}aminophenyl)] \\ 4\hbox{-}(cyclopropylmethyl)\hbox{-}1\hbox{-}piperazinyl] \\ methyl]\hbox{-}\textit{N},\textit{N}\hbox{-}diethyl\hbox{-}benzamide;$

N,N-diethyl-4-[(R)-[4-(2-propenyl)-1-piperazinyl][3-[(2-thienylmethyl)amino]phenyl]methyl]-benzamide;

N,N-diethyl-4-[(*R*)-[4-(3-methyl-2-butenyl)-1-piperazinyl][3-[(2-thienylmethyl)amino]phenyl]methyl]-benzamide;

4-[(*R*)-[4-(cyclopropylmethyl)-1-piperazinyl][3-[(2-thienylmethyl)amino]phenyl]methyl]-*N*,*N*-diethyl-benzamide;

4-{(S)-[3-(cyclohexylamino)phenyl][4-(cyclopropylmethyl)piperazin-1-yl]methyl}-N,N-diethylbenzamide;

4-[(S)-[3-(cyclohexylamino)phenyl](4-propylpiperazin-1-yl)methyl]-N,N-diethylbenzamide;

4-[(S)-[3-(cyclohexylamino)phenyl](4-ethylpiperazin-1-yl)methyl]-N,N-diethylbenzamide;

4-{(S)-(4-allylpiperazin-1-yl)[3-(cyclohexylamino)phenyl]methyl}-N,N-diethylbenzamide;

4-[(S)-{3-[(cyclohexylcarbonyl)amino]phenyl}(piperazin-1-yl)methyl]-N,N-diethylbenzamide;

4-[(S)-{3-[(cyclohexylacetyl)amino]phenyl}(piperazin-1-yl)methyl]-N,N-diethylbenzamide;

4-[(S)-{3-[cyclohexyl(methyl)amino]phenyl}(piperazin-1-yl)methyl]-N,N-diethylbenzamide;

4-[(R)-{3-[cyclohexyl(methyl)amino]phenyl}(piperazin-1-yl)methyl]-N,N-diethylbenzamide; enantiomers thereof; and pharmaceutically acceptable salts thereof.

11-12. (Cancelled)

Claim 13. (previously presented) A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

Claim 14. (previously presented) A method for the therapy of pain in a warm-blooded animal, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to claim 1.

Claims 15 -16. (cancelled)

Claim 17. (original) A process for preparing a compound of formula II, comprising:

a) reacting a compound of formula III:

with a compound of formula IV

in the presence of a base having a pKa of more than 15 wherein X is a halogen.

Claim 18. (original) A process for preparing a compound of formula VI:

Application No. 10/533,764 Amendment Dated: February 5, 2007

Reply to Office Action mailed October 2, 2006 and Advisory Action mailed January 10, 2007

comprising: reacting a compound of formula II

with a compound of formula VII

in the presence of SOX2 to form the compound of formula VI, wherein

 R^3 is selected from -H, C_{1-6} alkyl-O-C(=O)-, C_{1-6} alkyl, C_{3-6} cycloalkyl, and C_{3-6} cycloalkyl- C_{1-4} alkyl, wherein said C_{1-6} alkyl-O-C(=O)-, C_{1-6} alkyl, C_{3-6} cycloalkyl, and C_{3-6} cycloalkyl- C_{1-4} alkyl are optionally substituted with one or more groups selected from C_{1-6} alkyl, halogenated C_{1-6} alkyl, - NO_2 , -CF₃, C_{1-6} alkoxy and halogen; and

X is halogen.

Claim 19. (Currently Amended) A process for preparing a compound of formula I,

Application No. 10/533,764

Amendment Dated: February 5, 2007

Reply to Office Action mailed October 2, 2006 and Advisory Action mailed January 10, 2007

comprising: reacting a compound of formula VIII,

with R⁹-CHO in the presence of a reducing agent to form the compound of formula I: wherein

 R^{1} is R^{9} -CH₂-, wherein R^{9} is selected from phenyl, pyridyl, thienyl, furyl, imidazolyl, triazolyl, pyrrolyl, thiazolyl, N-oxido-pyridyl, benzyl, pyridylmethyl, thienylmethyl, furylmethyl, imidazolylmethyl, triazolylmethyl, pyrrolylmethyl, thiazolylmethyl and N-oxido-pyridylmethyl, optionally substituted with one or more groups selected from C_{1-4} alkyl, halogen, -CF₃, -OH, C_{1-3} alkoxy, phenoxy and halogen;

R² is -H: and

 R^3 is selected from C_{1-6} alkyl-O-C(=O)-, C_{1-6} alkyl, C_{3-6} cycloalkyl, and C_{3-6} cycloalkyl- C_{1-4} alkyl, wherein said C_{1-6} alkyl-O-C(=O)-, C_{1-6} alkyl, C_{3-6} cycloalkyl, and C_{3-6} cycloalkyl- C_{1-4} alkyl are optionally substituted with one or more groups selected from C_{1-6} alkyl, halogenated C_{1-6} alkyl, - NO_2 , -CF₃, C_{1-6} alkoxy and halogen.

Claim 20. (Currently Amended) A process for preparing a compound of formula IX,

Application No. 10/533,764

Amendment Dated: February 5, 2007

Reply to Office Action mailed October 2, 2006 and Advisory Action mailed January 10, 2007

comprising: reacting a compound of formula VIII,

with R⁸-Y-X or R⁸-Y-O-Y-R⁸ to form the compound of formula IX: wherein

X is halogen;

Y is selected from -C(=O)- and $-S(=O)_2$ -;

R⁸ is selected from C₃₋₆alkyl, C₆₋₁₀aryl, C₂₋₆heteroaryl, C₆₋₁₀aryl-C₁₋₄alkyl, C₂₋₆heteroaryl-C₁₋₄alkyl, C₃₋₁₀cycloalkyl, and C₃₋₁₀cycloalkyl-C₁₋₄alkyl; wherein said C₃₋₆alkyl, C₆₋₁₀aryl, C₂₋₆heteroaryl, C₆₋₁₀aryl-C₁₋₄alkyl, C₂₋₆heteroaryl-C₁₋₄alkyl, $\underline{C_{3-10}}$ cycloalkyl $\underline{C_{3-6}}$ eycloalkyl, and $\underline{C_{3-10}}$ cycloalkyl-C₁₋₄alkyl $\underline{C_{3-6}}$ eycloalkyl $\underline{C_{1-4}}$ alkyl are optionally substituted with C₁₋₄alkyl, halogen, -CF₃, -OH, C₁₋₃alkoxy, phenoxy, and halogen; and

 R^3 is selected from C_{1-6} alkyl-O-C(=O)-, C_{1-6} alkyl, C_{3-6} cycloalkyl, and C_{3-6} cycloalkyl- C_{1-4} alkyl, wherein said C_{1-6} alkyl-O-C(=O)-, C_{1-6} alkyl, C_{3-6} cycloalkyl, and C_{3-6} cycloalkyl- C_{1-4} alkyl are optionally substituted with one or more groups selected from C_{1-6} alkyl, halogenated C_{1-6} alkyl, - NO_2 , -CF₃, C_{1-6} alkoxy and halogen.

Claim 21. (Currently Amended) A process for preparing a compound of formula IX,

comprising: reacting a compound of formula VIII,

with R⁸-Z to form the compound of formula IX: wherein

Z is selected from –NCO and -NCS;

Y is selected from -C(=O)NH- and -C(=S)NH-;

 R^8 is selected from C_{3-6} alkyl, C_{6-10} aryl, C_{2-6} heteroaryl, C_{6-10} aryl- C_{1-4} alkyl, C_{2-6} heteroaryl- C_{1-4} alkyl, C_{3-10} cycloalkyl, and C_{3-10} cycloalkyl- C_{1-4} alkyl; wherein said C_{3-6} alkyl, C_{6-10} aryl, C_{2-6} heteroaryl- C_{1-4} alkyl, C_{3-10} cycloalkyl C_{3-6} cycloalkyl, and C_{3-10} cycloalkyl- C_{1-4} alkyl, C_{3-6} cycloalkyl- C_{1-4} alkyl are optionally substituted with C_{1-4} alkyl, halogen, C_{3-10} Cycloalkyl- C_{1-3} alkoxy, phenoxy, and halogen; and

 R^3 is selected from C_{1-6} alkyl-O-C(=O)-, C_{1-6} alkyl, C_{3-6} cycloalkyl, and C_{3-6} cycloalkyl- C_{1-4} alkyl, wherein said C_{1-6} alkyl-O-C(=O)-, C_{1-6} alkyl, C_{3-6} cycloalkyl, and C_{3-6} cycloalkyl- C_{1-4} alkyl are optionally substituted with one or more groups selected from C_{1-6} alkyl, halogenated C_{1-6} alkyl, - NO_2 , -CF₃, C_{1-6} alkoxy and halogen.